C4 Therapeutics Inc. (CCCC)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
C4 Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 90 | $236.7 | $334.28 | $97.58 | 41.23% |
 Farallon Capital Farallon Capital Management LLC | 28,000 | $228,760 | $104,720 | -$124,040 | -54.22% |
 Point72 Asset Management LP Point72 Asset Management LP | 169,096 | $322,973.34 | $633,264.52 | $310,291.18 | 96.07% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 25,740 | $48,026.2 | $96,512.13 | $48,485.93 | 100.96% |
 Li Peng China Universal Asset Management Co. Ltd. | 17,316 | $55,205.85 | $65,714.22 | $10,508.37 | 19.03% |
C4 Therapeutics Inc. (CCCC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has C4 Therapeutics Inc. ever had a stock split?
C4 Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Andrew J. Hirsch CEO | NASDAQ (NGS) Exchange | 12529R107 CUSIP |
| US Country | 104 Employees | - Last Dividend | - Last Split | 2 Oct 2020 IPO Date |
Overview
C4 Therapeutics, Inc. stands as a pioneering clinical-stage biopharmaceutical company, dedicated to the invention of novel therapeutic candidates aimed at degrading disease-causing proteins. Operating within a sphere that encompasses the treatment of cancer, neurodegenerative disorders, and an array of other diseases, the company utilizes cutting-edge technology to target and decompose proteins responsible for these conditions. Established in 2015, and with its headquarters in Watertown, Massachusetts, C4 Therapeutics embarks on strategic collaborations with leading entities like F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., Biogen MA, Inc., Betta Pharmaceuticals, Co., Ltd., Merck Sharp & Dohme, LLC, alongside Calico Life Sciences LLC. These partnerships bolster its trajectory towards achieving breakthroughs in the medical field, particularly in the realm of disease-associated protein degradation.
Products and Services
The core of C4 Therapeutics' mission is encapsulated in its development pipeline, highlighted by several key product candidates in clinical trials, namely:
- CFT7455: An innovative, orally bioavailable MonoDAC degrader specifically targeting the proteins IKZF1 and IKZF3, with the primary focus on treating multiple myeloma and non-Hodgkin lymphomas. This includes specific cancer types such as peripheral T-cell lymphoma and mantle cell lymphoma. Currently, CFT7455 is under a Phase 1/2 clinical trial, marking a significant step forward in the company's quest to deliver novel cancer therapies.
- CFT1946: This product candidate falls under the category of orally bioavailable BiDAC degraders, with a focus on targeting the V600X mutant BRAF. The aim here is the treatment of melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, among other solid malignancies. CFT1946 is presently undergoing Phase 1/2 clinical trials, representing a pivotal stride towards combating various solid tumor cancers with precision medicine.
- CFT8919: Distinguished as an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of the epidermal growth factor receptor (EGFR) harboring the L858R mutation in NSCLC. CFT8919 embodies the company's efforts to tailor treatments to specific genetic mutations in cancer, thereby paving the way for highly targeted and effective therapeutic options. This candidate too is currently in Phase 1/2 clinical trials, underscoring C4 Therapeutics' commitment to addressing unmet needs in NSCLC treatment through innovative degradation technology.
